Description: Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.
Home Page: www.cipherpharma.com
CPH Technical Analysis
209 Oak Park Boulevard
Oakville,
ON
L6H 0M2
Canada
Phone:
905 602 5840
Officers
| Name | Title |
|---|---|
| Mr. Craig J. Mull | Interim CEO & Chairman |
| Dr. Diane Gajewczyk | VP of Scientific & Medical Affairs |
| Mr. Bryan Jacobs | Chief Financial Officer |
| Mr. Emilio Presti | Director of Sales, Marketing & Hospital Bus. |
| Chuoru Li | Corp. Controller |
| David Miller | Director of Fin. |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 8.9847 |
|---|---|
| Trailing PE: | 7.7813 |
| Price-to-Book MRQ: | 1.5675 |
| Price-to-Sales TTM: | 4.4047 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |